United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - hadlima is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. hadlima can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). hadlima is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. hadlima can be used alone or in combination with methotrexate. hadlima is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. hadlima can be used alone or in combination with non-biologic dmards. hadlima is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. hadlima is indicated for reducing signs and symptoms

United States - English - NLM (National Library of Medicine)

organon llc - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - hadlima is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. hadlima can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). hadlima is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. hadlima can be used alone or in combination with methotrexate. hadlima is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. hadlima can be used alone or in combination with non-biologic dmards. hadlima is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. hadlima is indicated for the treatment of moderately

Australia - English - Department of Health (Therapeutic Goods Administration)

lima orthopaedics australia pty ltd - 48093 - reverse shoulder prosthesis head - a reverse shoulder glenosphere is made of uhmwpe x-lima + ti6al4v and is intended to be attached to the reverse shoulder base plate with a connector and screw and articulates with the reverse shoulder liner. the reverse glenosphere is part of the smr reverse shoulder system and is indicated for partial or total, primary or revision shoulder joint replacement in patients suffering from disability. in cases with a deficient and unreconstructable rotator cuff, a hemiprosthesis with a cta head or a reverse total shoulder arthroplasty is indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

lima orthopaedics australia pty ltd - 48092 - reverse shoulder prosthesis cup - the reverse liner is made of uhmwpe x-lima and is for uncemented with the addition of screws for fixation or cemented use. the reverse liner articulates with the reverse humeral body. the smr reverse liner is part of the smr reverse shoulder system that is indicated for primary, fracture or revision total shoulder replacement in a grossly rotator cuff deficient joint with severe arthropathy (disabled shoulder).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 5.69 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; isopropyl myristate; glyceryl laurate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 1.97 mg - drug delivery system, transdermal - excipient ingredients: glyceryl laurate; ethyl oleate; isopropyl myristate; acrylates/acrylamide copolymer - other condition: do not remove from primary pack except for immediate use. for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 7.6 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 3.8 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; glyceryl laurate; ethyl oleate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of the signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

piramal critical care pty ltd - fentanyl citrate, quantity: 78.5 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride - sublimaze is indicated for analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; use as a narcotic analgesic supplement in general and regional anaesthesia; administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - dostarlimab, quantity: 500 mg/ml - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; arginine hydrochloride; sodium chloride; polysorbate 80; water for injections; citric acid monohydrate - jemperli is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dmmr)/microsatellite instability-high (msi-h) endometrial cancer.,jemperli is indicated as monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dmmr) endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.